Atrasentan: Targeting the endothelin axis in prostate cancer

Antonio Jimeno, Michael Carducci

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


Endothelin axis deregulation triggers a series of events that lead to a profound deregulation in cancer cells, including key tumorigenic cellular events such as proliferation, invasion, escape from programmed cell death, new vessel formation, abnormal osteogenesis and the alteration of nociceptive stimuli. Atrasentan is a novel agent that effectively targets this pathway and is able to inhibit and/or reverse several of those events. Biological and clinical activity in patients with prostate cancer has been demonstrated in a Phase III clinical setting by the suppression of markers of biochemical and clinical prostate cancer progression, and by a delay in time to disease progression, especially in patients with bone disease.

Original languageEnglish (US)
Pages (from-to)1631-1640
Number of pages10
JournalExpert Opinion on Investigational Drugs
Issue number12
StatePublished - Dec 2004


  • Atrasentant
  • Endothelin I
  • Endothelin receptor A
  • Prostate cancer

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Atrasentan: Targeting the endothelin axis in prostate cancer'. Together they form a unique fingerprint.

Cite this